Bio-Rad to Acquire AbD Serotec for $69.7M | GenomeWeb

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories announced yesterday that it has signed a definitive agreement to acquire antibody manufacturer AbD Serotec for €53 million ($69.7 million) in cash.

Bio-Rad is acquiring the firm from its current parent, German company MorphoSys, and expects to complete the deal in January.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.